A Study of Isoprinosine in Patients With Lymph Node Disease
Launched by NEWPORT PHARMACEUTICALS INTERNATIONAL · Aug 30, 2001
Trial Information
Current as of June 12, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
MALE
Eligibility criteria
- • Exclusion Criteria
- Co-existing Condition:
- • Patients with a history of gout, uric acid urolithiasis, uric acid nephrolithiasis, renal dysfunction, or gastric ulceration are excluded.
- Concurrent Medication:
- Excluded:
- • Systemic corticosteroids.
- • Cytotoxic immunosuppressive agents.
- • Radiotherapy.
- • Critically ill patients or those with CDC-defined AIDS are excluded.
- Prior Medication:
- Excluded within 1 month of study entry:
- • Immunotherapy.
- • Patients with persistent generalized lymphadenopathy (PGL).
About Newport Pharmaceuticals International
Newport Pharmaceuticals International is a leading biopharmaceutical company dedicated to advancing innovative therapies that address unmet medical needs across various therapeutic areas. With a strong focus on research and development, Newport Pharmaceuticals harnesses cutting-edge science and technology to create effective treatments aimed at improving patient outcomes. The company is committed to conducting rigorous clinical trials that adhere to the highest ethical standards, ensuring safety and efficacy while fostering collaboration with healthcare professionals and regulatory bodies. Through its dedication to innovation and excellence, Newport Pharmaceuticals International strives to make a meaningful impact on global health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Laguna Hills, California, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials